ZVRA Q4 2021 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+9.1% YoY

Gross Profit

$3M97.7% margin

Operating Income

-$3M-110.1% margin

Net Income

-$3M-104.7% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+31.4%

Cash Flow

Operating Cash Flow

-$848,000

Free Cash Flow

-$865,000

Stock-Based Comp.

$823,000

Balance Sheet

Total Assets

$133M

Total Liabilities

$6M

Stockholders' Equity

$127M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+9.1%
Gross Profit	$3M	$2M	+6.6%
Operating Income	-$3M	-$3M	+11.6%
Net Income	-$3M	-$5M	+44.3%